The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Lemur tyrosine kinase 3 (LMTK3) plays a significant role in oncogenesis.
• LMTK3 is recognized as a potential therapeutic target for various cancers.

Purpose of the Study:

• To identify and characterize a novel, highly selective small molecule inhibitor of LMTK3.
• To evaluate the therapeutic potential of the identified inhibitor in cancer models.

Main Methods:

• In vitro and cell-based assays were employed.
• Biophysical analyses, including microscale thermophoresis (MST), were utilized.
• The inhibitor's effect was tested on the National Cancer Institute (NCI)-60 cancer cell line panel and breast cancer cell lines.

Main Results:

• A highly selective LMTK3 inhibitor, C36, was identified.
• C36 demonstrated significant in vitro selectivity and therapeutic effects across the NCI-60 panel.
• Microscale thermophoresis confirmed the binding affinity between LMTK3 and C36.
• C36 exhibited mixed-type inhibition, binding to both ATP and substrate sites.
• Treatment with C36 reduced proliferation and increased apoptosis in breast cancer cell lines.

Conclusions:

• C36 is a potent and selective LMTK3 inhibitor with demonstrated therapeutic efficacy.
• The findings support the development of LMTK3 inhibitors as a promising strategy for cancer therapy.